RegulatoryNews: <\/p>\n
NANOBIOTIX (Paris:NANO) (Euronext: NANO ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announces its revenue for the second quarter of 2014. <\/p>\n
Income statement <\/p>\n
Of which : <\/p>\n
License Services <\/p>\n
45,847 2,749 <\/p>\n
91,190 2,749 <\/p>\n
45,847 2,722 <\/p>\n
Activity <\/p>\n
The revenue recorded by NANOBIOTIX during the second quarter of 2014 relates to the upfront payment (pro-rata share) from the Taiwan-based PharmaEngine within the framework of the licensing contract. This licensing contract was signed in August 2012 for the development and commercialization of Nanobiotixs lead product, NBTXR3 in the Asia-Pacific region. It is distributed using the straight-line method across the period between the date the contract was signed and the scheduled marketing launch in the region. This upfront payment totaled 810,640, generating a product of 45,847 for the period and totalling 91,190 for the first semester in 2014. The invoicing of services totalled 2,749 for the second quarter of 2014. In total, revenue for the second quarter amounts 48,596. Revenue for the first half of 2014 is 93,939 which is fully in line with Company expectations. <\/p>\n
<\/p>\n
Here is the original post: RegulatoryNews: NANOBIOTIX (Paris:NANO) (Euronext: NANO ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announces its revenue for the second quarter of 2014. Income statement Of which : License Services 45,847 2,749 91,190 2,749 45,847 2,722 Activity The revenue recorded by NANOBIOTIX during the second quarter of 2014 relates to the upfront payment (pro-rata share) from the Taiwan-based PharmaEngine within the framework of the licensing contract. Continue reading
\nNanobiotix revenue for the 2nd quarter of 2014<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"